Meghan Logun

2024 NCI-FDA Interagency Oncology Task Force Fellow
Postdoc at @PennMedicine studying cellular immunotherapies for GBM
Neuro PhD from @universityofga

[Penn Medicine @PennMedicine]

For the first time, Penn Medicine researchers grew #glioblastoma organoids in the lab that accurately mirrored what was happening in patients' brains as they were treated with #CARTcelltherapy. Read more about the research here: https://t.co/44eZazGUHK

[Penn Neurosurgery @PennNSG]

Now online in @CellStemCell, our researchers used #glioblastoma organoids to assess CAR-T clinical trial responses in real time.

@DrORourke2 @StephenBagleyMD @LogunMeghan @sun_yusha @XinW_up @UPenn_SongMing @MacNasrallah @danzhang122 @EmilyllPai

➡️ https://t.co/cTVuYBF9Av

[DrORourke @DrORourke2]

Patient-derived glioblastoma organoids as real-time avatars for assess... https://t.co/MGZYFFoT0V
Happy to report our work using #GBM organoids to predict #CART response in #glioblastoma @PennCancer

[Yusha Sun @sun_yusha]

Our recent work on the use of glioblastoma organoids (GBOs) to assess CAR-T clinical trial responses in real time together with @LogunMeghan @XinW_up @StephenBagleyMD @UPenn_SongMing @DrORourke2 is now online @CellStemCell!

[Neil Renic @NC_Renic]

Fortunately, the academic job market has prepared me for crushing disappointment

[Meghan Logun @LogunMeghan]

Want to avoid doomscrolling election coverage for 30 mins this morning?

[Axion BioSystems @axionbio1]

Hey scientists! 👋👩‍🔬 Have about 30 mins on Nov. 5th? Join Axion BioSystems, Immuno-Oncology Insights, and Dr. Meghan Logun for a new webinar by registering today via the link 🔗https://t.co/WeyynUH6XH #CARTcell #Organoids #Glioblastoma

[Daniel Zhang @danzhang122]

So excited to share this study looking at the dynamic interplay between GBM and CAR T cells during treatment using organoids and single cell multi-omics! Hopefully this moves us toward a better understanding of #immunotherapy in #GBM. Huge thanks to @UPenn_SongMing @DrORourke2!

[Daniel Zhang @danzhang122]

Also, a big shout out to @LogunMeghan @sun_yusha @XinW_up @StephenBagleyMD for their extraordinary work using GBM organoids as high-fidelity real-time models for CAR T cell therapy testing in parallel with a clinical trial https://t.co/C2jpviVszn

[Meghan Logun @LogunMeghan]

If you’re feeling down about the state of scientific collaboration today, get inspired by the backstory of the incredible new paper from @kpmueller1 and @EvanWeberPhD out in @Nature now!!!

[Kat Mueller, PhD @kpmueller1]

I'm wildly proud to share our FIRST Weber Lab paper, out today in @Nature! I want to share a story about how this whirlwind of a project came together. A 🧵 on teamwork, open science, and how far we can go when we intentionally build a culture of trust in research. 1/

[Neil Renic @NC_Renic]

Pre-PhD: I'm not that clever

Post-PhD: I have a sophisticated grasp of precisely how stupid I am in multiple fields

[Penn Medicine @PennMedicine]

Early results from a #glioblastoma clinical trial show that a “dual-target” #CART cell therapy approach appears to shrink brain tumors and may be a promising step toward cell therapy for solid tumors. @PennCancer @PennNSG @DrORourke2 @NatureMedicine https://t.co/43hdSIXVOs

[Meghan Logun @LogunMeghan]

Check out early responses from our ongoing trial on dual targeting CARs for EGFR AND IL13Ra2 for GBM out in @NatureMedicine today 😎

[Saheli Sadanand @SaheliSadanand]

🌟NEW in @NatureMedicine: bivalent #CARTcells targeting EGFR *and* IL13Ra2 are feasible to make & well tolerated in patients with #glioblastoma. No ORs but reductions in tumor size seen. Congrats to @DrORourke2, @StephenBagleyMD & co-authors! @PennMedicine https://t.co/jVjk3QVRjq

[Stephen Bagley @StephenBagleyMD]

Excited to share our early phase 1 results for bivalent #CARTcells in recurrent #glioblastoma. Now online @NatureMedicine. Awesome team effort! @PennMedicine @PennCancer @PennNSG @DrORourke2

https://t.co/xppeeXv74x

[Gritty @GrittyNHL]

tell ur mom i luv her, thx

[Meghan Logun @LogunMeghan]

Lucky for everyone I am still at my poster until 5 today! Come say hi in section 35, number 18 ! #AACR2023

[Penn Medicine MD @PennMDForum]

Researchers from @PennMedicine @PennCancer have 18 posters at #AACR23, including this one from @LogunMeghan @DrORourke2 featuring preclinical work to make CAR T cell therapy more effective in glioblastoma.

[DrORourke @DrORourke2]

Data from our 2nd CART GBM trial @PennMedEVDCSO @PennCancer @PennNSG is out in preprint form as we hope to continue to define better cell therapy and I-O combinations for #Glioblastoma

[Meghan Logun @LogunMeghan]

This work was an immensely fun experience and what propelled me towards cellular immunotherapies for GBM! Special thanks to @kpmueller1 for the free inspiration

[Translational Glycomaterials and Neural Repair Lab @karumbaiahlab]

(2/2) Grateful for the opportunity to work with immensely talented collaborators @sahakris, @CapitiniMD, @Art_Edison, Theresa Kotanchek,@DanielJBrat, and @ChvatalStacie. https://t.co/a3tPeDU7lR #biomanufacturing #immunotherapy #nsf @CMaT_ERC supported.

[Meghan Logun @LogunMeghan]

@NicoleJPiscopo @kpmueller1 HAHA I’m pretty sure that noncompliance is gonna be against the law this weekend @kpmueller1 go birds

[CSH @CSHLaboratory]

Happy to announce @CSHLaboratory will be starting our own social media service! WatsonWatsoff will provide free verification for all faculty (with beards). Everyone else will need a new Cell/Sci/Nature paper a month to keep their verification.

[Meghan Logun @LogunMeghan]

“We hacked your iCloud and will post all your pictures unless you send us $5000”
Um please chill out, those are all articles I swear I’m going to read some day